Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nirmatrelvir→

Nirmatrelvir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2628280-40-8
Molecular formula
C23H32F3N5O4
Molecular weight
499.5 g/mol
Drug class
SARS-CoV-2 main protease (3CLpro/Mpro) inhibitorantiviral component of Paxlovid
Mechanism of action
Selectively inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication. It is administered with ritonavir, which inhibits CYP3A-mediated metabolism and increases nirmatrelvir exposure.
Indications / reported uses
  • In combination with ritonavir (PAXLOVID) for treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalisation or death, under the applicable product label; nirmatrelvir monotherapy is not the authorised regimen

Sources: US DailyMed — PAXLOVID (nirmatrelvir/ritonavir), label updated 2026 · US FDA — Paxlovid prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

SARS-CoV-2 main protease (3CLpro/Mpro) inhibitor; antiviral component of Paxlovid

Mechanism of action

Selectively inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication. It is administered with ritonavir, which inhibits CYP3A-mediated metabolism and increases nirmatrelvir exposure.

General use cases

  • In combination with ritonavir (PAXLOVID) for treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalisation or death, under the applicable product label; nirmatrelvir monotherapy is not the authorised regimen

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Nirmatrelvir Environmental Risk Assessment (ERA) (the Nirmatrelvir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.